Form 4: Corcept CBO Exercises Options, Sells Shares for Tax

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, exercised stock options and subsequently sold shares, partially to cover taxes.

Summary

• Gary Charles Robb, Chief Business Officer of CORCEPT THERAPEUTICS INC (CORT), reported transactions on August 22, 2025.
• Exercised 5,000 stock options at an exercise price of $3.88 per share, acquiring 5,000 shares of common stock.
• Sold 2,326 shares of common stock at a price of $71.27 per share.
• Disposed of 2,674 shares of common stock at $71.17 per share to satisfy the exercise price and tax liability from the net (cashless) exercise of options.
• Following these transactions, direct beneficial ownership of common stock is 13,364 shares, which includes 503, 290, 292, and 997 shares underlying unvested restricted stock awards granted on September 3, 2024, December 2, 2024, March 3, 2025, and June 2, 2025, respectively.
• Indirect beneficial ownership includes 23,142 shares held in two separate custodial accounts for a child under the Uniform Transfers to Minors Act.
• Retains 145,000 stock options (right to buy) with an exercise price of $3.88 per share, which are fully exercisable and expire on February 26, 2026.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving option exercise and subsequent share sales, including tax-related dispositions, which is a common practice and generally considered neutral.

Positives

• The exercise of stock options at a significantly lower price ($3.88) compared to the market price at the time of sale (approximately $71) indicates a substantial personal gain for the insider.
• The option exercise demonstrates the value of the company's equity compensation program.

Negatives

• The sale of 2,326 shares by an insider, even if routine, represents a reduction in their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may note the insider selling, but the context of option exercise and tax withholding often mitigates negative perception, as it is a common liquidity event for executives.
• The disclosure of shares held in custodial accounts for a child provides transparency regarding the insider's total beneficial ownership.

Next Steps

• The remaining unvested restricted stock awards will vest on the one-year anniversary of their respective grant dates, provided the reporting person satisfies certain requirements.

Key Dates

Recommendation

The filing details a routine insider transaction where the Chief Business Officer exercised stock options and subsequently sold a portion of the shares to cover the exercise cost and tax liabilities. This is a common practice and does not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this report.

Keywords

Corcept Therapeutics, CORT, Insider Transaction, Stock Option Exercise, Share Sale, Gary Charles Robb, Chief Business Officer, SEC Form 4